Bozitinib (PLB-1001)

Catalog No.S6762 Synonyms: CBT-101, APL-101, CBI-3103

For research use only.

Bozitinib (PLB-1001, CBT-101, APL-101, CBI-3103) is a highly selective ATP-competitive c-Met inhibitor with blood-brain barrier permeability. Bozitinib (PLB-1001) selectively inhibits MET-altered tumor cells in preclinical models.

Bozitinib (PLB-1001) Chemical Structure

CAS No. 1440964-89-5

Purity & Quality Control

Choose Selective c-Met Inhibitors

Other c-Met Products

Biological Activity

Description Bozitinib (PLB-1001, CBT-101, APL-101, CBI-3103) is a highly selective ATP-competitive c-Met inhibitor with blood-brain barrier permeability. Bozitinib (PLB-1001) selectively inhibits MET-altered tumor cells in preclinical models.
Targets
c-Met [1]

Protocol (from reference)

Solubility (25°C)

In vitro

Chemical Information

Molecular Weight 424.38
Formula

C20H15F3N8

 

CAS No. 1440964-89-5
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CN1C=C2C=C(C(=CC2=N1)F)C(C3=NN=C4N3N=C(C=C4)C5=CN(N=C5)C6CC6)(F)F

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04743505 Recruiting Drug: APL-101|Drug: Osimertinib Metastatic Non Small Cell Lung Cancer Washington University School of Medicine|Apollomics Inc. January 18 2022 Phase 1|Phase 2
NCT02978261 Completed Drug: PLB1001 Glioma Beijing Pearl Biotechnology Limited Liability Company September 2016 Phase 1
NCT02896231 Completed Drug: PLB1001 Non-Small Cell Lung Cancer Beijing Pearl Biotechnology Limited Liability Company April 2016 Phase 1

(data from https://clinicaltrials.gov, updated on 2022-08-01)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Bozitinib (PLB-1001) | Bozitinib (PLB-1001) supplier | purchase Bozitinib (PLB-1001) | Bozitinib (PLB-1001) cost | Bozitinib (PLB-1001) manufacturer | order Bozitinib (PLB-1001) | Bozitinib (PLB-1001) distributor